Celldex Therapeutics, Inc. — Director's Dealing 2024

Jun 17, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2024-06-13

Reporting Person: Jimenez Freddy A. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-06-13	Incentive Stock Option (right to buy)	$36.43	A	75000	Acquired	2034-06-13	Common Stock (75000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2: 25% vest on June 13, 2025 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.